SCHEMBL5651779

SCHEMBL5651779

C=C(CNC)c1ccc(NC(=O)C(F)(F)F)c(C2=CCCCC2)c1

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 17/20 0.63
KIT P10721 2/20 0.37
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653089 0.86 CSF1R (0.68) CSF1RKITCYP2C9
SCHEMBL5650146 0.82 CSF1R (0.66) CSF1RKIT
Trifluoroacetic Acid SCHEMBL5651781 0.82 CSF1R (0.59) CSF1RCYP2C9
Trifluoroacetic Acid SCHEMBL5651777 0.80 CSF1R (0.57) CSF1RCYP2C9
SCHEMBL14384980 0.77 CSF1R (0.66) CSF1RKIT
SCHEMBL4188266 0.77 CSF1R (0.43) CSF1RKITCYP2C9
SCHEMBL14383567 0.75 CSF1R (0.73) CSF1RKITCYP2C9
SCHEMBL14383372 0.75 CSF1R (0.66) CSF1RKITCYP2C9
SCHEMBL3082962 0.73 CSF1R (0.57) CSF1R
SCHEMBL3083546 0.72 CSF1R (0.60) CSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452996-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-09-27 US disclosed
EP-2021329-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-04-13 EP disclosed
US-20160046602-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-02-18 US disclosed
US-9221797-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2015-12-29 US disclosed
US-20140148448-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
US-8674100-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2014-03-18 US disclosed
EP-2687516-A1 Inhibitors of C-FMS Kinase Janssen Pharmaceutica N.V. (BE) 2014-01-22 EP disclosed
US-20070249649-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249649-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885KIT 114/4885CYP2C9 2219/4885
US-20140148448-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885KIT 114/4885CYP2C9 2219/4885
US-20160046602-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885KIT 114/4885CYP2C9 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.